Fiche société
Hospital for Special Surgery, New York
Traitements, essais et publications liés.
Traitements1programmes
Essais1liés
Publications4liées
SourceDBlocale
Traitements
1| Molécule | Indication / population | Phase | Objectif | Pays | Résultat |
|---|---|---|---|---|---|
| Cyclophosphamide LDPrimary objective: Safety and tolerability of NKX019, administered after lymphodepletion (LD). Secondary objectives: * Assess clinical activity of NKX019 in subjects with systemic lupus erythematosus (SLE) with or without active lupus nephritis (LN) * Characterize pharmacokinetics (PK) of NKX019 * Characterize immunogenicity of NKX019 | Lupus | Phase 1 | À vérifier | United States | À vérifier |
Essais cliniques
1| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| NKX019 | Lupus | Phase 1 | NCT06518668 | A Study of NKX019, a CD19 CAR NK Cell Therapy, in Subjects With Systemic Lupus Erythematosus | ENROLLING_BY_INVITATION |
Publications
4| Molécule | Indication / population | Titre | Journal | Date |
|---|---|---|---|---|
| Cyclophosphamide LD | A combined Ames and in vivo genotoxicity assessment of dimyricetin-yl-diselenide, a structurally defined organoselenium flavonoid. | Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association | ||
| Cyclophosphamide LD | Impact of fludarabine dosage on outcomes in large B-cell lymphoma patients treated with CAR T-cell therapy: a retrospective study of the CTIWP of the EBMT. | Bone marrow transplantation | ||
| Cyclophosphamide LD | Bendamustine-based lymphodepletion prior to CAR T-cell therapy: a systematic review. | Bone marrow transplantation | ||
| Cyclophosphamide LD | Comparison of Fludarabine Versus Bendamustine as a Lymphodepleting Chemotherapy Prior to CAR-T for Large Cell Lymphoma. | Transplantation and cellular therapy |